Asan Medical Center
Seoul, 138-736, South Korea
NCT Number: NCT01905566
Objectives: To compare the effects of clopidogrel versus ticagrelor on atherosclerotic plaque inflammation using serial FDG PET/CT imaging of carotid artery and ascending aorta.
Hypothesis: Thrombosis and inflammation are tightly linked rather than separate entities. Therefore, P2Y12 receptor inhibitors may have an anti-ischemic effect by inhibiting plaque inflammation, and ticagrelor may be superior in efficacy to clopidogrel.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 4
Seoul, 138-736, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
75mg once a day
90mg twice a day
Time frame: 6months
Analyses of FDG activity will be quantified on common carotid arteries and ascending aorta of the aortic arch. Primary endpoint is change (follow-up minus baseline) in standardized FDG uptake value within the regions of interest, known as a target-to-background ratio(blood-normalized standardized uptake value).
Time frame: 6months
Time frame: 6months
lipid battery (total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol).
CHEOL WHAN LEE, M.D., Ph.D
Other
Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation: Serial FDG PET/CT Imaging Study of Carotid Artery and Ascending Aorta
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03064126
Arterial Occlusive Diseases, Arteriosclerosis
Fairhope, Alabama, United States
View Trial DetailsNCT02316886
Arterial Occlusive Diseases, Arteriosclerosis
New York, United States
View Trial DetailsNCT01709045
Brain Diseases, Cardiovascular Diseases
Maastricht, Limburg, Netherlands
View Trial DetailsNCT02212470
Arterial Occlusive Diseases, Arteriosclerosis
São Paulo, Brazil
View Trial Details